NovoCure: Pay

NovoCure paid its 6 named executives $36.4M in total in FY2025 (Dec). CEO Frank Leonard was paid $7.0M of that.

Pay$100 in the stock at the end of FY22 → $18
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Ashley CordovaFormer Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years
Frank LeonardChief Executive Officer
FY2025 (Dec)
FY2024 (Dec)Not disclosed
FY2023 (Dec)Not disclosed
3 years
Christoph BrackmannChief Financial Officer
FY2025 (Dec)
1 year
Uri WeinbergChief Medical and Innovation Officer
FY2025 (Dec)
FY2024 (Dec)
2 years
Nicholas LeupinFormer Chief Medical Officer
FY2025 (Dec)
1 year
Michael PuriChief Human Resources Officer
FY2025 (Dec)
1 year

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 12 peers with pay on file was $11.1M. CEO pay of NovoCure for that year is not on file.

  1. 1Exelixis
  2. 2Incyte
  3. 3Align Technology
  4. 4Insulet
  5. 5Alnylam Pharmaceuticals
  6. 6Teladoc Health
  7. 7TransMedics Group
  8. 8Immunocore Holdings
  9. 9Zai Lab
  10. 10Inspire Medical Systems
  11. 11CRISPR Therapeutics AG
  12. 1210x Genomics
  13. 13NovoCureNot disclosed
  14. 14BeOne MedicinesNot disclosed
  15. 15Blueprint MedicinesNot disclosed
  16. 16Exact Sciences CorporationNot disclosed
  17. 17Guardant HealthNot disclosed
  18. 18iRhythm TechnologiesNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.